In a recent transaction, Beth C. Seidenberg, a director at Vera Therapeutics, Inc. (NASDAQ:VERA), sold a significant number of shares in the company. The sale, which took place over two days, involved a total of 16,476 shares of Class A Common Stock, resulting in proceeds of over $696,000.
On September 18, Seidenberg sold 1,177 shares at a weighted-average price of approximately $42.01, with the price ranging from $42.00 to $42.07. The same day, another batch of 1,476 shares was sold at a flat rate of $42.00 per share. The following day, Seidenberg continued to divest, selling 13,823 shares at a weighted-average price of $42.31, with prices ranging from $42.00 to $42.79.
These sales were conducted under a Rule 10b5-1 trading plan, which Seidenberg had adopted on June 19, 2024. This plan allows company insiders to set up a predetermined schedule for buying or selling stocks at a time when they are not in possession of material non-public information, providing a defense against claims of insider trading.
Following these transactions, Seidenberg’s direct holdings in the company have been adjusted, with the exact amount of shares owned after the sales being disclosed in footnotes to the SEC filing. In particular, the footnotes reveal that prior indirect beneficial ownership included shares held by entities associated with Kleiner Perkins Caufield & Byers XVI, LLC, which underwent pro-rata in-kind distributions of shares to its members, including Seidenberg.
Investors and followers of Vera Therapeutics often monitor such insider transactions as they can provide insights into the executives’ perspectives on the company’s current valuation and future prospects. The company, which operates within the pharmaceutical preparations industry, is incorporated in Delaware and has its business address in Brisbane, California.
In other recent news, Vera Therapeutics continues to make significant strides in the biopharmaceutical sector. JPMorgan has raised its price target for Vera Therapeutics from $62.00 to $72.00, maintaining an Overweight rating. This increase comes as the company progresses with the development of its lead drug candidate, atacicept, currently in mid to late-stage clinical trials. The drug has been granted Breakthrough Therapy Designation by the FDA based on promising Phase 2b ORIGIN trial data, suggesting potential improvements in kidney function for patients with IgA nephropathy.
In addition to these developments, Vera Therapeutics has welcomed David Johnson as Chief Operating Officer and Christy Oliger to its board of directors. Johnson, with his extensive experience in the pharmaceutical industry, will oversee the company’s operations, and his compensation package includes a $500,000 annual base salary and an option to purchase 160,000 shares of Vera Therapeutics Class A common stock.
Meanwhile, Wedbush analysts have maintained their Outperform rating on Vera Therapeutics and increased the share price target to $34 from $21. These recent developments underscore Vera Therapeutics’ ongoing advancements in the sector.
InvestingPro Insights
In light of the recent insider transactions at Vera Therapeutics, Inc. (NASDAQ:VERA), it’s beneficial for investors to consider the company’s financial health and market performance. According to InvestingPro data, Vera Therapeutics currently holds a market capitalization of $2.34 billion. Despite a challenging financial outlook with a negative P/E ratio of -19.18, indicating that the company is not currently profitable, its share price has seen a significant return over the last year, with a 156.19% increase.
InvestingPro Tips suggest that while Vera Therapeutics has a strong cash position, holding more cash than debt, analysts are concerned about its profitability. They have revised their earnings expectations downwards for the upcoming period, and the consensus is that the company will not be profitable this year. Moreover, the company is trading at a high Price / Book multiple of 7.15, which may suggest that the stock is valued quite optimistically by the market, especially given the lack of profitability in the last twelve months.
The recent insider sales by Beth C. Seidenberg could be interpreted in various ways, but with the backdrop of the company’s financial metrics and analyst sentiment, investors may want to delve deeper into the company’s strategy and outlook. For those looking for more detailed analysis and additional tips, InvestingPro offers a comprehensive list of tips, with 13 additional insights available for Vera Therapeutics at https://www.investing.com/pro/VERA, which could further inform investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
